Targeting LSD1 and FOXA1 in prostate cancer

FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature genetics 2020-10, Vol.52 (10), p.1002-1003
Hauptverfasser:	Omarjee, Soleilmane, Carroll, Jason S.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/200 631/337/176 631/67/589/466 Agriculture Androgen receptors Androgens Animal Genetics and Genomics Biomedical and Life Sciences Biomedicine Cancer Research Chromatin Demethylation Enzymes Gene expression Gene Function Hepatocyte Nuclear Factor 3-alpha - genetics Hepatocyte Nuclear Factor 3-alpha - metabolism Histone Demethylases - genetics Histone Demethylases - metabolism Human Genetics Humans Ligands Male Methylation News & Views news-and-views Prostate cancer Prostatic Neoplasms - genetics Proteins Therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resistant prostate cancer.
ISSN:	1061-4036 1546-1718
DOI:	10.1038/s41588-020-0702-6